FDA approves NeuroBo’s DA-1726 application to begin Phase I trial

FDA approves NeuroBo’s DA-1726 application to begin Phase I trial

Source: 
Clinical Trials Arena
snippet: 

The US Food and Drug Administration (FDA) has approved NeuroBo Pharmaceuticals’ investigational new drug (IND) application for DA-1726 to commence a Phase I clinical trial to treat obesity.